StockData
Kyntra Bio, Inc. logo

Kyntra Bio, Inc. (KYNB) company profile

KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$2.04−1.16 (-36.25%)

Close on Nov 17, 2026Market cap $8.26MP/E 0.0Yield –

About Kyntra Bio

Pharmaceutical Preparations, SIC 2834

Kyntra Bio, Inc. is a biopharmaceutical company engaged in the research, clinical development, and commercialization of pharmaceutical drug candidates. The company operates through business streams that include drug product manufacturing and supply as well as research, development, and licensing arrangements. Its primary lead product candidates comprise roxadustat and FG-3246, which is developed in conjunction with the positron emission tomography imaging agent FG-3180. Its principal customers and commercial counterparties include major multinational pharmaceutical partners such as Astellas and AstraZeneca, who collaborate on product development and commercial distribution.

Geographically, the company maintains business operations, commercial relationships, and licensing arrangements across several key global markets, including the United States, Europe, Japan, and China. It also maintains corporate ties to entities located in Finland and the Cayman Islands, while executing the sale of its roxadustat business in China. Kyntra Bio is incorporated in Delaware and operates its principal executive offices in San Francisco, California.

Summary of the business section of Kyntra Bio's latest annual report, written by StockData.

Company profile

Company

Legal name
Kyntra Bio, Inc.
Founded
1993
Headquarters
San Francisco, CA
Address
350 Bay Street, Suite 100 #6009 94133
Phone
(415) 978-1200
Employees
34, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Irvine, California

Stock & identifiers

Ticker
KYNB
Former tickers
FGEN until Mar 16, 2026
Exchange
Nasdaq
IPO date
Nov 14, 2014
Shares outstanding
4M, Jul 31, 2026
Public float
$21.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-25 reverse, Jun 17, 2025
SEC CIK
921299
CUSIP
31572Q881
ISIN
US31572Q8814
FIGI
BBG000FW5ZL6
Share class FIGI
BBG001SN7DS0
LEI
549300Q914ULWWY95822
EIN
77-0357827

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Thane WettigCEO, Director29,336
David DeLuciaChief Financial Officer4,355
Christine ChungSVP, CHINA OPERATIONS294,544
Juan GrahamCHIEF FINANCIAL OFFICER164,863
Andrew E. SingerDirector–
Maykin HoDirector37,726
Michael KauffmanDirector–
James A. SchoeneckDirector68,432
Jeffrey L. EdwardsDirector38,601

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
First Peo
$2.11M$1.46M$1.15M$2–
FY2025
Second Peo
$0$0$1.15M$2–
FY2024
First Peo
$2.64M$1.55M$1.04M$3–
FY2024
Second Peo
$0$0$1.04M$3–
FY2023
First Peo
$3.64M-$85.60K$3.13M$6–
FY2023
Second Peo
$7.44M-$4.79M$3.13M$6–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 14, 2014
Offer price
$18.00
Securities offered
8,100,000
Gross proceeds
$145.80M
Exchange
Nasdaq
First trading day
Nov 14, 2014
First-day close
$22.00+22.2%
Lock-up ends (est.)
May 13, 2015

“The initial public offering price per share is $18.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We had 34 employees in the U.S.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?